What's breaking now, across thousands of outlets.
Some research suggests that GLP-1 drugs may raise the risk of a rare eye disease that causes full or partial vision loss.
We haven't written up this one. MarketWatch has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
Under an agreement reached years ago, the state is to spend at least 1 percent of GDP on research and development. However, funding may fall short of that target in the coming years.
PureGym is seeking to raise £1.4 billion ($1.9 billion) from the high-yield bond market to refinance outstanding debt that may cut the gym operator’s borrowing costs.
The market focus is set to turn to American data releases
Nvidia said on Monday that it would it had approved plans to expand its overall buyback program to $235 billion, the biggest in stock market history.
The sale of Portuguese water utility Indaqua has been delayed after potential bidders requested additional information before submitting their binding offers, according to people familiar with the…
This under-the-radar food distribution stock boasts a Superscore of 74 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.
